Alphapharm

15 PBAC submissions on file, active 2005–2024. 60% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Cetuximab
  Oncology · Recommended · 2024other sponsor
• Etanercept
  Rheumatology · Recommended with restriction · 2025other sponsor
• Nicotinic acid
  Cardiovascular · Not recommended · 2007—
• Adrenaline
  Immunology · Deferred · 2018other sponsor
• Bevacizumab
  Oncology · Recommended · 2024other sponsor
• Insulin glargine
  Endocrinology · Recommended · 2018—
• Losartan
  Cardiovascular · Recommended · 2010—
• Pegfilgrastim
  Oncology · Recommended · 2020other sponsor
• Rifampicin
  Infectious disease · Recommended · 2020—
• Rivaroxaban
  Cardiovascular · Noted · 2024other sponsor
• Tenofovir disoproxil maleate with emtricitabine
  Infectious disease · Recommended with restriction · 2017—
• Trastuzumab
  Oncology · Recommended · 2021other sponsor

Therapy area mix

Activity by year

2005 (1) · 2006 (1) · 2007 (2) · 2010 (1) · 2016 (1) · 2017 (1) · 2018 (2) · 2019 (1) · 2020 (1) · 2021 (2) · 2022 (1) · 2024 (1)

Rejection patterns

Across 6 Not recommended decisions on file.

• 1×unacceptably high cost compared with comparator (approximately forty times greater AEMP than adrenaline ampoule)
• 1×lack of evidence to support clinical claims of superior ease and timeliness of administration
• 1×inadequate evidence for decreased risk of overdosing
• 1×high potential for wastage due to short shelf-life in Prescriber Bag context
• 1×uncertain clinical benefit